Quarterly report pursuant to Section 13 or 15(d)

Balance Sheet Components (Tables)

v3.19.2
Balance Sheet Components (Tables)
6 Months Ended
Jun. 30, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Components of Accrued Liabilities

Accrued liabilities were comprised of the following (in thousands):

 

 

 

June 30,

 

 

December 31,

 

 

 

2019

 

 

2018

 

Accrued liabilities:

 

 

 

 

 

 

 

 

General and administrative

 

$

1,059

 

 

$

297

 

Clinical trial related costs

 

 

1,355

 

 

 

598

 

Non-clinical research and manufacturing operations

 

 

3,140

 

 

 

2,644

 

Payroll related

 

 

1,510

 

 

 

1,787

 

Other accrued expenses

 

 

56

 

 

 

31

 

Total accrued liabilities

 

$

7,120

 

 

$

5,357

 

Components of Deferred Revenue

 

Deferred revenue was comprised of the following:

 

 

 

June 30,

 

 

December 31,

 

 

 

2019

 

 

2018

 

Deferred revenue:

 

 

 

 

 

 

 

 

Research and development agreements

 

$

16,225

 

 

$

28,901